
Scribe Therapeutics Presents New Data Advancing the Potential of Ultra-Long-Acting Genetic Medicines for Cardiovascular Disease at AHA Scientific Sessions 2026
|
November 18, 2026
X min read
- Single dose of STX-1150 prototype lowered LDL-C by >50% for at least two years in non-human primates without permanent DNA modification, supporting the potential for ultra-long-acting cholesterol control with reduced treatment burden; repeat dosing in NHPs enabled further LDL-C lowering while maintaining tolerability
- STX-1200 surrogate achieved >95% Lp(a) reduction in non-human primates, without detectable off-target editing in primary human hepatocytes, reinforcing the potential for a potent and precise one-time Lp(a)-lowering therapy designed to recapitulate genetic protection of low Lp(a)
- Results reinforce Scribe’s approach to addressing a critical unmet need in cardiovascular care: ultra-long-acting therapies designed to sustainably and substantially lower atherogenic lipoproteins and empower patients to prevent disease before it develops
|
November 18, 2026
Share on Social
More like this
Media
Scribe Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
November 13, 2026
Read Now

Press
Scribe Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
November 13, 2026
Read Now
Media
Scribe Therapeutics to Participate in Upcoming Healthcare Investor Conferences
November 5, 2026
Read Now
Press
Scribe Therapeutics to Participate in Upcoming Healthcare Investor Conferences
November 5, 2026
Read Now
Media
Scribe Therapeutics to Present Updated Data on PCSK9-Targeting Epigenetic Silencing and LPA-Targeting Gene Editing Programs at American Heart Association (AHA) Scientific Sessions 2026
November 4, 2026
Read Now

Press
Scribe Therapeutics to Present Updated Data on PCSK9-Targeting Epigenetic Silencing and LPA-Targeting Gene Editing Programs at American Heart Association (AHA) Scientific Sessions 2026
November 4, 2026
Read Now